Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
This is a single-arm, non-randomized study of ARQ 501 in combination with gemcitabine in adult patients with treatment-naïve, unresectable, metastatic pancreatic adenocarcinoma. The study objectives are: Primary Objective: * Assess the overall response rate (ORR) of patients treated with ARQ 501 in combination with gemcitabine. Secondary Objectives: * Determine time to tumor progression (TTP) of patients treated with ARQ 501 in combination with gemcitabine * Further characterize the safety of ARQ 501 in combination with gemcitabine
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted